Monica Ganan

Dr. Monica Ganan

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Food Control
Verified
Journal Article
Closed access
MGMonica Ganan
Monica Ganan
EHEva Hierro
Eva Hierro
XHXavier Fernández Hospital
Xavier Fernández Hospital
EBElvira Barroso
Elvira Barroso
MFManuela Fernández
Manuela Fernández

1 August 2012 in International Journal of Food Microbiology
Verified
Journal Article
Closed access
EHEva Hierro
Eva Hierro
MGMonica Ganan
Monica Ganan
EBElvira Barroso
Elvira Barroso
MFManuela Fernández
Manuela Fernández

1 August 2009 in Food Control
Verified
Journal Article
Closed access
MGMonica Ganan
Monica Ganan
Adolfo J. Martinez-RodriguezAdolfo J. Martinez-Rodriguez
Adolfo J. Martinez-Rodriguez
ACAlfonso V. Carrascosa
Alfonso V. Carrascosa

1 August 2009 in Journal of Food Protection
Verified
Journal Article
Closed access
MGMonica Ganan
Monica Ganan
ACA. V. Carrascosa
A. V. Carrascosa
AMAdolfo J. Martinez-Rodriguez
Adolfo J. Martinez-Rodriguez
The antimicrobial activities of three chitosans with different molecular masses against six gram-negative and three gram-positive bacteria were examined. Campylobacter spp. were the microorganisms ...

1 February 2010 in International Journal of Food Microbiology
Verified
Journal Article
Closed access
MGMonica Ganan
Monica Ganan
MCM. Collins
M. Collins
RRR. Rastall
R. Rastall
AHArland Hotchkiss
Arland Hotchkiss
HCH.K. Chau
H.K. Chau
Adolfo J. Martinez-RodriguezAdolfo J. Martinez-Rodriguez
Adolfo J. Martinez-Rodriguez

8 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MGMonica Ganan
Monica Ganan
SLSilje B Lorentzen
Silje B Lorentzen
JAJane W Agger
Jane W Agger
CHCatherine A Heyward
Catherine A Heyward
NNNn Nn
Nn Nn
MSMorten Sørlie
Morten Sørlie
Due to their antifungal activity, chitosan and its derivatives have potential to be used for treating yeast infections in humans. However, to be considered for use in human medicine, it is necessary to control and know the chemical composition of the compound, which is not always the case for polymeric chitosans. Here, we analyze the antifungal activity of a soluble and well-defined chito-oligosaccharide (CHOS) with an average polymerization degree (DPn) of 32 and fraction of acetylation (FA) of 0.15 (C32) on 52 medically relevant yeast strains. Minimal inhibitory concentrations (MIC) varied widely among yeast species, strains and isolates (from > 5000 to < 9.77 μg mL-1) and inhibition patterns showed a time- and dose-dependencies. The antifungal activity was predominantly fungicidal and was inversely proportional to the pH, being maximal at pH 4.5, the lowest tested pH. Furthermore, antifungal effects of CHOS fractions with varying average molecular weight indicated that those fractions with an intermediate degree of polymerization, i.e. DP 31 and 54, had the strongest inhibitory effects. Confocal imaging showed that C32 adsorbs to the cell surface, with subsequent cell disruption and accumulation of C32 in the cytoplasm. Thus, C32 has potential to be used as a therapy for fungal infections.